Xeris Biopharma Holdings, Inc. (XERS) — DEF 14A Filings
All DEF 14A filings from Xeris Biopharma Holdings, Inc.. Browse 2 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (2)
-
Xeris Biopharma Files 2024 Executive Compensation Details
— Apr 23, 2025 Risk: medium
Xeris Biopharma Holdings, Inc. filed its DEF 14A on April 23, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing in -
Xeris Biopharma Holdings, Inc. Files Definitive Proxy Statement
— Apr 23, 2024 Risk: low
Xeris Biopharma Holdings, Inc. (XERS) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Filing type is DEF 14A, filed on 2024-04-23. Reporting p
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX